Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy

BACKGROUND: KRAS mutations may predict poor response to radiotherapy. Downstream events from KRAS, such as activation of BRAF, AKT and ERK, may also confer prognostic information but have not been tested in rectal cancer (RC). Our objective was to explore the relationships of KRAS and BRAF mutation...

Descripción completa

Detalles Bibliográficos
Autores principales: Davies, Janine M, Trembath, Dimitri, Deal, Allison M, Funkhouser, William K, Calvo, Benjamin F, Finnegan, Timothy, Weck, Karen E, Tepper, Joel E, O'Neil, Bert H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180690/
https://www.ncbi.nlm.nih.gov/pubmed/21910869
http://dx.doi.org/10.1186/1748-717X-6-114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180690/
https://www.ncbi.nlm.nih.gov/pubmed/21910869
http://dx.doi.org/10.1186/1748-717X-6-114

Ejemplares similares